<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03723148</url>
  </required_header>
  <id_info>
    <org_study_id>FEDR</org_study_id>
    <nct_id>NCT03723148</nct_id>
  </id_info>
  <brief_title>Individual Patient Compassionate Use of Fedratinib</brief_title>
  <official_title>Compassionate Use of Fedratinib for Patients Who Have Previously Received TG101348, SAR302503 or Fedratinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Celgene</source>
  <brief_summary>
    <textblock>
      This is an expanded access program (EAP) for eligible participants designed to provide access
      to fedratinib.

      Expanded access is only available in markets where fedratinib is not yet approved.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This program is being offered on a patient by patient basis and will require company,
      Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.
    </textblock>
  </detailed_description>
  <overall_status>Available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_individual>Yes</expanded_access_type_individual>
  </expanded_access_info>
  <condition>Myelofibrosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Fedratinib</intervention_name>
    <description>Oral fedratinib administered as directed by treating physician.</description>
    <other_name>FEDR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will be considered if they received TG101348, SAR302503 or Fedratinib as a
        participant on a clinical trial prior to 31 Jan 2018.

        Exclusion Criteria:

        Subject is eligible for enrollment in an ongoing clinical trial using Fedratinib or has
        been treated with Fedratinib after 31 Jan 2018.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Celgene Medical Information</last_name>
    <phone>1-888-771-0141</phone>
    <email>medinfo@celgene.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celgene</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Available</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 25, 2018</study_first_submitted>
  <study_first_submitted_qc>October 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2018</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Expanded Access</keyword>
  <keyword>Compassionate Use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Myelofibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

